4//SEC Filing
Deschatelets Pascal 4
Accession 0001127602-24-012710
CIK 0001492422other
Filed
Apr 8, 8:00 PM ET
Accepted
Apr 9, 4:25 PM ET
Size
10.7 KB
Accession
0001127602-24-012710
Insider Transaction Report
Form 4
Deschatelets Pascal
Chief Scientific Officer
Transactions
- Sale
Common Stock
2024-04-08$54.12/sh−64,379$3,483,966→ 1,120,711 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-04-08−69,107→ 37,280 totalExercise: $3.76Exp: 2026-02-07→ Common Stock (69,107 underlying) - Sale
Common Stock
2024-04-08$54.92/sh−4,728$259,639→ 1,115,983 total - Exercise/Conversion
Common Stock
2024-04-08$3.76/sh+69,107$259,842→ 1,185,090 total
Footnotes (5)
- [F1]This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
- [F2]This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
- [F3]This transaction was executed in multiple trades at prices ranging from $53.770 - $54.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $54.775 - $55.750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This stock option was granted on 02/08/2016 and is fully vested.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001657720
Filing Metadata
- Form type
- 4
- Filed
- Apr 8, 8:00 PM ET
- Accepted
- Apr 9, 4:25 PM ET
- Size
- 10.7 KB